

# Is this the extinction of ESR, the dinosaur laboratory test?

Many laboratories have historically clung onto the ESR (Erythrocyte Sedimentation Rate) as a test which can confirm that patients are unwell.

Even though the science behind ESR is seen as dubious by laboratory scientists, and many clinicians

including Consultant Haematologists, the question that remains unanswered is why we are still requesting it?

Is it just out of habit that we continue to use a test which has no quality control and results will vary without any change in the patient condition? Aspirin and Steroids are the backbone of many treatments for patients with inflammation, and yet they are the very drugs that will significantly interfere with the ESR results, suggestive of an improvement which may not have occurred.

Plasma Viscosity (PV) testing was seen as the 'cure' for this habit more than 30 years ago, and yet this 'easy to use', rapid, stable diagnostic tool has been overlooked by many laboratories as the high volume alternative. Over the years more and more laboratories have elected to use Plasma Viscosity testing as a significant tool within their repertoire. Some noteworthy centres of excellence have taken the ambitious commitment to eliminate ESR in preference for PV including Leeds General Infirmary, Royal United Hospital Bath, Nobles Hospital IOM and Royal Devon and Exeter.

Recently the momentum for change appears to have taken some significant steps forward in the laboratory drive for increased efficiency and modernisation, as more sites across the UK signal a sea change in breaking age old habits around ESR.

NHS Highland and Hull Royal Infirmary (HEY NHS Trust) are the latest Trusts to have abandoned their ESR testing in preference for PV by working with their clinical community to drive that change. The laboratories took advantage of a reorganisation in Haematology, to overhaul the service and move to a more efficient system.

*You need to be able to get consistent results in order to provide useful data for the clinical community. With PV we have internal and external QC (CQAS). Due to the excellent data CQAS provide and the total number of Benson analysers the consistency is easily observable. The manual ESR system did not have its own QC and no external quality control was available. Mick Milner NHS Highland*

These new sites have been able to provide some insight into how they achieved the change with the full support of their clinical colleagues. Together with the longer term experiences of the Royal Devon and Exeter Hospital (RD&E), a **process route map** has been developed, and could be followed by those laboratories that would also like to eliminate ESR testing, potentially reduce costs and provide the means to monitor post acute phase inflammatory disease progression.

## Process route map to introduce routine Plasma Viscosity testing

### Successful Change Steps

#### Assessment:

- Review of clinical picture and patient data repeatedly shows that PV provides a more consistent indicator of disease progression and demonstrates the clinical significance of very small ( 0.05mPas) changes
- Duplicate test data for ESR and PV shows there is no conversion table between the two systems

#### Consultation with specialist clinicians and GP's to highlight:

- The simplification of the test profile by the potential elimination of additional blood collection tubes (PV can use the full blood count sample)
- Improvements due to plasma sample stability and viscosity testing quality control
- Rheumatology/Speciality patient monitoring change to CRP for acute phase
- Handling of clinical trial requirements

#### Issue notice period for the switch to PV:

- Include summary evidence for the change
- Include table for results interpretation
- Plan for a short switch over period

#### Support Clinicians and specialities to make the final move:

- Provide laboratory staff with training to answer questions from clinicians.

#### Seek feedback:

A focus on 4 key areas was identified during the consultation to support the transition period: Rheumatology, Orthopaedics, Clinical Trials and GP's.

NHS Highland found that some basic clinical trial packages used ESR testing results due to clinical convention. Discussions revealed that the ESR results themselves did not alter patient management neither did the majority of trials really require its use.

Clinical trial test packages included ESR out of habit rather than need

The Royal Devon and Exeter (RD&E) hospital managed to eliminate all ESR testing 4 years ago. Steve Walton, Haematology Laboratory Manager at the RD&E explained that the only area of difficulty was for one WW clinical trial. A drug used as part of a hip replacement procedure was only available following an ESR test result. This drug authorisation protocol is not routinely seen in arthritic hip replacement surgery.

CRP and not ESR is used to test for patient infection during the critical phase of hip replacement surgery.

The **Orthopaedic surgeons** and the **Microbiologists** routine plan of action is the continued use of CRP to check for the acute phase inflammatory response in a two stage operation where the patient's new hip is only inserted if there is no sign of infection. Once the critical phase is completed then PV testing is routinely used to monitor.

Similarly, **NHS Highland Rheumatologists** use routine CRP test for tracking patient progress with disease assessment scores and were able to eliminate ESR.

**The consultation and support processes were handled as critical steps** in reviewing the potential for changing away from ESR testing. NHS Highland Consultant Haematologist Dr Peter Forsyth drove the decision to make the change only after preparing the evidence base, where it was found that PV provided the laboratory with consistent, stable and reproducible data. This enables the requesting clinicians to plot disease progression with cumulative PV data. The information was provided as part of a consultation of the GPs and Hospital Consultants and with the question – what would happen if we withdrew ESR? The decision overall was that PV would provide a suitable alternative.

*Having put a good evidence base together we found that PV gave us consistent data, it was easier, a separate specimen tube was not required and with increased numbers would provide some additional financial savings.*

Mick Milner goes on to explain that education is critical. The clinicians require clear information of what a PV result means because the range appears limited.

Compared with wide ESR scale of <8 mm to 120 mm, the PV normal range is only 1.50 to 1.72 cp. The laboratory has been posting additional information on their reports to assist the clinician's interpretation

**Time and sample transportation** can give significant challenges for any integrated system involving several laboratories and GP point of care services. Both NHS Highland and HEY NHS Trusts found that switching to PV testing helped them overcome difficulties in managing the return of samples from outlying clinics.

*The test became pointless when specimens arrived from outlying areas already 24 hours old. We made the decision to stop providing the ESR within our test repertoire. PV's on the other hand provided a stable repeatable result, a major consideration given our unique geography. Mick Milner NHS Highland*

**Feedback can be very satisfying** As one of the most important vehicles for communication and process improvements, the prospect of adverse feedback often causes some trepidation. Across all three Trusts, the feedback received was very positive.

*There were a lot of glowing comments from the feedback questionnaires. The only complaint we received was that the turn around time was now too quick - glowing praise indeed. Elaine Boyle, Haematology Service Manager Hull Royal Infirmary, HEY NHS Trust.*

With special thanks to;

Elaine Boyle, Haematology Service Manager HEY NHS Trust

Dr Peter Forsyth, Consultant Haematologist, NHS Highland

Mick Milner, Haematology Manager, NHS Highland

Steve Walton, Laboratory Manager Royal Devon & Exeter NHS Trust